InsiderTrades.com logo

AKTX Insider Trading

Insider Ownership Percentage: 38.50%
Insider Buying (Last 12 Months): $38,659.93
Insider Selling (Last 12 Months): $0.00

Akari Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Akari Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akari Therapeutics Share Price & Price History

Current Price: $0.34
Price Change: +0.30 (1.20%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for AKTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Akari Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2025Abizer GaslightwalaCEOBuy3,000$0.90$2,700.00298,574View SEC Filing Icon  
8/22/2025Abizer GaslightwalaCEOBuy8,000$0.93$7,440.00295,574View SEC Filing Icon  
8/21/2025Abizer GaslightwalaCEOBuy10,000$0.94$9,400.00287,574View SEC Filing Icon  
6/24/2025Abizer GaslightwalaCEOBuy5,203$1.16$6,035.48277,574View SEC Filing Icon  
6/23/2025Abizer GaslightwalaCEOBuy943$1.15$1,084.45272,371View SEC Filing Icon  
6/20/2025Abizer GaslightwalaCEOBuy10,000$1.20$12,000.00271,428View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Akari Therapeutics (NASDAQ:AKTX)

5.06% of Akari Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AKTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Akari Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/12/2025Cresset Asset Management LLC822,468$0.83M0.0%+4,368.0%2.522%Search for SEC Filing on Google Icon
11/6/2025Omnia Family Wealth LLC28,440$29K0.0%-54.6%0.087%Search for SEC Filing on Google Icon
7/28/2025Omnia Family Wealth LLC62,690$73K0.0%-28.5%0.195%Search for SEC Filing on Google Icon
2/5/2024Omnia Family Wealth LLC87,628$0.27M0.1%+48.2%1.551%Search for SEC Filing on Google Icon
11/15/2023Sabby Management LLC178,091$0.70M0.5%-97.6%3.152%Search for SEC Filing on Google Icon
11/14/2022Armistice Capital LLC4,290,000$2.70M0.0%N/A5.762%Search for SEC Filing on Google Icon
10/27/2022Omnia Family Wealth LLC782,372$0.49M0.4%+3.2%1.051%Search for SEC Filing on Google Icon
5/6/2022Omnia Family Wealth LLC758,144$0.91M0.6%+13.7%1.277%Search for SEC Filing on Google Icon
4/13/2022Hikari Power Ltd130,821$0.16M0.0%+45.7%0.220%Search for SEC Filing on Google Icon
2/10/2022Wsfs Capital Management LLC100,000$0.15M0.1%N/A0.193%Search for SEC Filing on Google Icon
2/4/2022Omnia Family Wealth LLC667,085$1M0.6%+42.8%1.285%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Akari Therapeutics logo
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Read More on Akari Therapeutics

Today's Range

Now: $0.34
Low: $0.32
High: $0.36

50 Day Range

MA: $0.70
Low: $0.34
High: $1.05

52 Week Range

Now: $0.34
Low: $0.29
High: $1.73

Volume

507,983 shs

Average Volume

1,003,204 shs

Market Capitalization

$12.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of Akari Therapeutics?

Akari Therapeutics' top insider investors include:
  1. Abizer Gaslightwala (CEO)
Learn More about top insider investors at Akari Therapeutics.

Who are the major institutional investors of Akari Therapeutics?

Akari Therapeutics' top institutional shareholders include:
  1. Cresset Asset Management LLC — 2.52%
  2. Omnia Family Wealth LLC — 0.09%
Learn More about top institutional investors of Akari Therapeutics stock.

Which major investors are selling Akari Therapeutics stock?

Within the previous quarter, AKTX stock was sold by these institutional investors:
  1. Omnia Family Wealth LLC

Which major investors are buying Akari Therapeutics stock?

Within the previous quarter, AKTX stock was purchased by institutional investors including:
  1. Cresset Asset Management LLC